The use of nonsteroidal anti - inflammatory drugs in polymorbid pathology


Cite item

Full Text

Abstract

The literature review presents the possibilities of using non - steroidal anti - inflammatory drugs (NSAIDs) for polymorbid pathology. The mechanism of NSAIDs action, risk factors for the development of undesirable effects on the cardiovascular, digestive, urinary and other systems are considered; prevention measures and drug selection options are discussed, NSAIDs prescribing algorithm is considered.

About the authors

N S Asfandiyarova

Ryazan State Medical University

Email: n.asfandiyarova2010@yandex.ru
д.м.н., доцент каф. поликлинической терапии и профилактической медицины ФГБОУ ВО «РязГМУ» Минздрава России; ORCID: 0000-0002-2025-8119 Ryazan, Russia

E V Philippov

Ryazan State Medical University

д.м.н., зав. каф. поликлинической терапии и профилактической медицины ФГБОУ ВО «РязГМУ» Минздрава России; ORCID: 0000-0002-7688-7176 Ryazan, Russia

References

  1. Ширинский В.С., Ширинский И.В. Коморбидные заболевания - актуальная проблема клинической медицины. Сибирский медицинский журнал. 2014;29(1):7-12. doi: 10.29001/2073-8552-2014-29-1-7-12
  2. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., Ивашкин В.Т., Чичасова Н.В., Алексеева Л.И. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23. doi: 10.14412/1996-7012-2015-1-4-23
  3. Theodoridou A, Gika H, Diza E, Garyfallos A, Settas L. In vivo study of pro - inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis. Mediterranian J Rheumatol. 2017;28(1):43-50. doi: 10.31138/mjr.28.1.43
  4. Metzner J, Popp L, Marian C, Schmidt R, Manderscheid C, Renne C, et al. The effects of COX-2 selective and non - selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J Molecular Medicine (Berlin). 2007;85(6):623-33. doi: 10.1007/s00109-007-0162-9
  5. Schmidt M, Lamberts M, Olsen A-MS, Fosbøll E, Niessner A, Tamargo J, et al. Cardiovascular safety of non - aspirin non - steroidal anti - inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015-23. doi: 10.1093/eurheartj/ehv505
  6. Varga Z, Sabzwari S, Vargova V. Cardiovascular Risk of Nonsteroidal Anti - Inflammatory Drugs: An Under-Recognized Public Health Issue Cureus. 2017 Apr; 9(4):e1144. Published online 2017 Apr 8. doi: 10.7759/cureus.1144 PMCID: PMC5422108
  7. Морозова Т.Е., Шмарова Д.Г., Рыкова С.М. Выбор нестероидных противовоспалительных препаратов у больных ревматологического профиля с сопутствующими сердечно - сосудистыми заболеваниями. Лечащий врач. 2016;(7):39-45.
  8. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non - steroidal anti - inflammatory drugs: meta - analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79. doi: 10.1016/S0140-6736(13)60900-9
  9. Зотова Л.А., Петров В.С. Нестероидные противовоспалительные препараты в современной клинической практике: фокус на безопасность. Наука молодых. 2015;(1):25-30.
  10. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов и ингибиторов циклооксигеназы-2 в начале XXI века. Русский Медицинский журнал. 2003;11(7):375-8.
  11. Чичасова Н.В., Имаметдинова Г.Р., Иголкина Е.В., Насонов Е.Л. Найз в лечении хронических заболеваний суставов. Русский Медицинский журнал. 2012;(17). https://medi.ru/info/11713/
  12. Patompong Ungprasert, Wonngarm Kittanamongkolchai, Chrystal Price, Supawat Ratanapo, Napat Leeaphorn, Daych Chongnarungsin, Wisit Cheungpasitporn. What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs? Am Medical J. 2012;3(2):115-23. doi: 10.3844/ amjsp.2012.115
  13. Каратеев А.Е., Новикова Д.С., Насонов Е.Л. Новые данные, касающиеся безопасности нестероидных противовоспалительных препаратов: представление о «класс - специфическом» высоком кардиоваскулярном риске селективных ингибиторов циклооксигеназы-2 устарело. Научно - практическая ревматология. 2017;55(2):218-23. doi: 10.14412/1995-4484-2017-218-223
  14. Gislason G.H, Rasmussen J.N, Abildstrom S.Z, Schramm T.K, Hansen M.L, Fosbol E.L, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti - inflammatory drugs in chronic heart failure. Archive Internal Medicine. 2009;169(2):141-9. doi: 10.1001/archinternmed.2008.525
  15. Martín Arias L.H, Martín González A, Sanz Fadrique R, Vazquez E.S. Cardiovascular Risk of Nonsteroidal Anti - inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta - analysis of Observational Studies. J Clin Pharmacol. 2019;59(1):55-73. doi: 10.1002/jcph.1302
  16. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Safety of Non - steroidal Anti - inflammatory Drugs (SOS) Project Consortium.Non - steroidal anti - inflammatory drugs and risk of heart failure in four European countries: nested case - control study. British Medical J. 2016;354(28):i4857. doi: 10.1136/bmj.i4857
  17. Nissen S.E, Yeomans N.D, Solomon D.H, Lüscher T.F, Libby P, Husni M.E, et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England J Medicine. 2016;375(26):2519-29. doi: 10.1056/NEJMoa1611593
  18. Slomski A. Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety. J Amer Medical Association. 2016;316(24):2589. doi: 10.1001/ jama.2016.19355
  19. Ruschitzka F, Borer J.S, Krum H, Flammer A.J, Yeomans N.D, Libby P, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282-92. doi: 10.1093/eurheartj/ehx508
  20. White W.B, Kloner R.A, Angiolillo D.J, Davidson M.H. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharm Ther. 2018;23(2):103-18. doi: 10.1177/1074248417751070
  21. Reed G.W, Riaz H, Wang Q, Wolski K, Wisniewski L, Menon V, et al. Comparison of the safety of celecoxib, ibuprofen, andnaproxen in patients without established cardiovascular diseases. J Amer College of Cardiol. 2019;73(9)(suppl 1). doi: 10.1016/S0735-1097(19)30637-0
  22. Балабанова Р.М. Влияние селективных ингибиторов ЦОГ2 на сердечно - сосудистую систему при ревматических заболеваниях. Современная ревматология. 2010;4(2):88-93. doi: 10.14412/1996-7012-2010-609
  23. Наумов А.В., Ткачева О.Н., Ховасова Н.О. К вопросу безопасности нестероидных противовоспалительных препаратов у пациентов с сердечно - сосудистым риском. Терапевтический архив. 2019;91(1):108-13. doi: 10.26442/ 00403660.2019.01.000039
  24. Лыгина Е.В. Эффективность и безопасность применения нимулида у больных остеоартрозом в сочетании с гипертонической болезнью. Российский медико - биологический вестник имени академика И.П. Павлова. 2006;(1):44-50.
  25. Ejaz P, Bhojani K, Joshi V.R. NSAIDs and Kidney. JAPI. 2004;52: 632-40. www.japi.org
  26. Dixit M, Doan T, Kirschner R, Dixit N. Significant Acute Kidney Injury Due to Non - steroidal Anti - inflammatory Drugs: Inpatient Setting. Pharmaceuticals (Basel). 2010;3(4):1279-85. doi: 10.3390/ph3041279
  27. Park K.E, Qin Y, Bavry A.A. Nonsteroidal anti - inflammatory drugs and their effects in the elderly. Aging Health. 2012;8(2):167-77.
  28. Leo R.J. Safe Analgesic Use in Patients with Renal Dysfunction. General guidelines for appropriate use of analgesics and co - analgesic adjuvants in pain patients with co - existing renal insufficiency. Practical Pain Management. 2014;8(5). https://www.practicalpainmanagement.com/treatments/pharmacologi cal/safe-analgesic-use-patients-renal-dysfunction?page=0,3
  29. Chih-Cheng Hsu, Hongjian Wang, Yueh-Han Hsu, Shao-Yuan Chuang, Ya-Wen Huang, Yu-Kang Chang, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension. Nationwide Longitudinal Cohort Study. Hypertension. 2015;66:524-33. doi:/10.1161/HYPERTENSIONAHA.114.05105
  30. Воронина H.B., Гельмутдинов Д.Д., Маркина О.И. Влияние нестероидных противовоспалительных препаратов - ингибиторов и не ингибиторов ЦОГ на состояние почек у больных оксалатной нефропатией, коморбидных по остеоартрозу. Дальневосточный медицинский журнал. 2016;1:14-9.
  31. Nelson D.A, Marks E.S, Deuster P.A, O’Connor F.G, Kurina L.M. Association of Nonsteroidal Anti - inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle - aged Adults. J Amer Medical Association Netw Open. 2019;2(2):e187896. Published online February 15. doi: 10.1001/jamanetworkopen.2018.7896
  32. Lai K.M, Chen T.L, Chang C.C, Chen H.H, Lee Y.W. Association between NSAID use and mortality risk in patients with end - stage renal disease: a population - based cohort study. Clin Epidemiol. 2019;11:429-41. doi: 10.2147/CLEP.S204322
  33. Tan J.H.Y, Hsu A.A.L. Nonsteroidal anti - inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link. Respiratori Medicine. 2016;118:1-3. doi: 10.1016/j.rmed.2016.07.004
  34. Bendlin B.B, Newman L.M, Ries M.L, Puglielli L, Carlsson C.M, Sager M.A, et al. NSAIDs may protect against age - related brain atrophy. Frontiers Aging Neuroscience. 03 September 2010. doi: 10.3389/fnagi. 2010.00035
  35. Johnson A.G, Day R.O. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging. 1991;1(2):130-43. doi: 10.2165/ 00002512-199101020-00005
  36. Stillman M.T. Interaction and Selection of Therapeutic Agents in the Elderly: NSAIDs and the Ageing Kidney. Scand J Rheumatol. 1989;18(suppl 82):33-8. doi: 10.3109/03009748909101467
  37. Маянская С.Д., Каменская Л.Ю. Проблемы безопасности применения НПВП у пожилых пациентов с остеоартрозом в амбулаторной практике врача - терапевта. Русский Медицинский журнал. 2007;(22):1656-9.
  38. Van Leen M.W.F, Van der Eijk I.A, Schols J.M.G. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes. Age and Ageing. 2007;36(4):414-8. doi: 10.1093/ageing/ afm049
  39. Makris U.E, Kohler M.J, Fraenkel L. Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review. J Rheumatol. 2010;37(6):1236-43. doi: 10.3 899/jrheum.090935
  40. Taylor Jr. R, Lemtouni S, Weiss K, Pergolizzi Jr. J.V. Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel’s View on Preventable Harm Associated with NSAID Therapy. Current Gerontology and Geriatrics Research. Volume 2012; Article ID 196159, 9 pages. doi: 10.1155/2012/196159
  41. Пахомова И.Г., Хорошинина Л.П. Особенности применения нестероидных противовоспалительных препаратов у пожилых. Журнал неврологии и психиатрии. 2016;11:169-73. doi: 10.17116/ jnevro2016116111169-173
  42. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in the Elderly. Aging Diseases. 2018 Feb;9(1):143-50. Published online 2018 Feb 1. doi: 10.14336/AD.2017.0306
  43. Danelich I.M, Wright S.S, Lose J.M, Tefft B.J, Cicci J.D, Reed B.N. Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease. Pharmacother. 2015;35(5):520-35. doi: 10.1002/phar.1584
  44. Milder T.Y, Williams K.M, Ritchie J.E, Lipworth W.L, Day R.O. Use of NSAIDs for osteoarthritis amongst older - aged primary care patients: engagement with information and perceptions of risk. Age and Ageing. 2011;40(2):254-9. doi: 10.1093/ageing/afq160
  45. EMA/696137/2012 Assessment report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and cardiovascular risk. www.ema.europa.eu
  46. Scarpignato C, Lanas A, Blandizzi C, Lems W.F, Hermann M, Hunt R.H, and For the International NSAID Consensus Group. Safe prescribing of non - steroidal anti - inflammatory drugs in patients with osteoarthritis - an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine. 2015;13:55. doi: 10.1186/s12916-015-0285-8
  47. Roshi D, Toçi E, Burazeri G, Schröder-Bäck P, Malaj L, Brand H. Users’ Knowledge About Adverse Effects of Non - steroidal Anti - inflammatory Drugs in Tirana, Albania. Mater Sociomed. 2017;29(2):138-42. doi: 10.5455/msm.2017.29.138-42

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies